| Kasie Lynn Myers, NP | |
|
2116 Craig Road, Eau Claire, WI 54701-6149 | |
| (715) 858-4500 | |
| Not Available |
| Full Name | Kasie Lynn Myers |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 2116 Craig Road, Eau Claire, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053017434 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 13580-33 (Wisconsin) | Primary |
| Entity Name | Marshfield Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952347981 PECOS PAC ID: 2264345206 Enrollment ID: O20031106000590 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
| Entity Name | Beaver Dam Community Hospitals Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972188555 PECOS PAC ID: 2567370539 Enrollment ID: O20040210000666 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
| Entity Name | Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346239373 PECOS PAC ID: 2365433224 Enrollment ID: O20040519001426 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
| Entity Name | Flambeau Hospital, Inc. |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1700963048 PECOS PAC ID: 9032029871 Enrollment ID: O20070828000478 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
| Entity Name | Memorial Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1346239373 PECOS PAC ID: 2365433224 Enrollment ID: O20110526000807 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
| Entity Name | Mchs Hospitals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093221434 PECOS PAC ID: 5698071173 Enrollment ID: O20180208000096 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
| Entity Name | Lakeview Medical Center Inc Of Rice Lake |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093201832 PECOS PAC ID: 6103737820 Enrollment ID: O20180817001484 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
| Entity Name | Mchs Hospitals Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1952890873 PECOS PAC ID: 5698071173 Enrollment ID: O20180904002962 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
| Entity Name | Signify Health Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750845863 PECOS PAC ID: 2163764424 Enrollment ID: O20191118000551 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
| Entity Name | Flambeau Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194317966 PECOS PAC ID: 9032029871 Enrollment ID: O20210409000059 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kasie Lynn Myers, NP 1000 N Oak Ave, Marshfield, WI 54449-5703 Ph: (715) 387-5511 | Kasie Lynn Myers, NP 2116 Craig Road, Eau Claire, WI 54701-6149 Ph: (715) 858-4500 |
News Archive
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.
› Verified 3 days ago
Hope C. St Jean, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 733 W Clairemont Ave, Eau Claire, WI 54701 Phone: 715-838-3311 | |
Mrs. Kaitlyn Anne Bodette, APNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-3311 | |
Brenda Lynn Marcy, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2240 Eastridge Ctr, Eau Claire, WI 54701 Phone: 715-838-7372 Fax: 715-838-2910 | |
Rhiannon C Riley, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger Street, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Ms. Heidi Elizabeth Back, CNM Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Carla Griggs, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5211 | |
Emily Anne Riechers, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 |